πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 41 pharma-relevant US patents (A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 12157729

Solid state forms of Belumosudil and Belumosudil salts

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Dec 03 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 28 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12139528

Treating refractory migraine

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Nov 12 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 07 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 12091388

Solid state forms of Reproxalap

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Sep 17 2024 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 12 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11813359

Sustained release olanzapine formulations

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Nov 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Nov 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11773083

Solid state forms of Belumosudil and Belumosudil salts

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Oct 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Sep 28 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11673860

Crystalline siponimod fumaric acid and polymorphs thereof

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jun 13 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 08 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11555064

Treating headache comprising administering an antibody to calcitonin gene-related peptide

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jan 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11541177

Injection spring for aged prefilled syringe and auto injector

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11420945

Solid state forms of Pemafibrate

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11306104

Solid state forms of Relugolix

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Apr 19 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Apr 14 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11220488

Crystalline polymorph of Ponesimod

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jan 11 2022 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 06 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11053261

Solid state forms of ixazomib citrate

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jul 06 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 01 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11028160

Treating refractory migraine

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 11028161

Treating refractory migraine

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jun 08 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 03 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10899826

Pharmaceutical compositions for an anti-CGRP antagonist antibody

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jan 26 2021 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10689352

Solid state forms of trisodium valsartan: sacubitril

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jun 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10676498

Processes for the preparation of sofosbuvir and intermediates thereof

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jun 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 04 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10646443

Sustained release olanzapine formulations

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue May 12 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10604537

Solid state forms of ixazomib citrate

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Mar 31 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10597448

Methods for treating visceral pain associated with interstitial cystitis by administering

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Mar 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10556945

Antagonist antibodies directed against calcitonin gene-related peptide and methods using s

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Feb 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10519224

Treating headache comprising administering an antibody to calcitonin gene-related peptide

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10392434

Treating refractory migraine

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Aug 27 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Aug 22 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10329343

Methods for treating headache using antagonist antibodies directed against calcitonin gene

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted